893.52
Argen X Se Adr (ARGX) 最新ニュース
Argenx SE Stock (NL0010832176): Analyst price target move puts biotech in focus - AD HOC NEWS
European ADRs Rose In US Trading As Biotech Led - Finimize
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says - Benzinga
Sanofi Scraps Its Argenx Rival; Why Another Biotech Took The Hit - Investor's Business Daily
ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know - TradingView
ARGX Stock Price, Quote & Chart - ChartMill
Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock? - Yahoo Finance
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference - Barchart.com
ARGX News | ARGENX SEADR (NASDAQ:ARGX) - ChartMill
H.C. Wainwright reiterates Buy on argenx stock, $940 target - Investing.com UK
H.C. Wainwright reiterates Buy on argenx stock, $940 target By Investing.com - Investing.com South Africa
Form 6K argenx NV ADR For: 3 June By Investing.com - Investing.com India
ARGX.BR Stock Price, Quote & Chart | ARGENX SE (EBR:ARGX) - ChartMill
Stifel raises argenx stock price target on myositis study outlook - Investing.com UK
Stifel raises argenx stock price target on myositis study outlook By Investing.com - Investing.com Australia
Barlow’s Research Roundup: RBC analyst provides praise and top picks in regulated utilities sector - The Globe and Mail
Argenx SE stock (NL0010832176): autoimmune drug specialist in focus after recent price strength - AD HOC NEWS
Evercore ISI Raises its Price Target on argenx (ARGX) - Yahoo Finance
Jefferies updates franchise picks list, adding AMZN, APP, MCD and more - MSN
argenx SE’s SWOT analysis: stock gains momentum on Vyvgart growth By Investing.com - Investing.com Nigeria
argenx SE’s SWOT analysis: stock gains momentum on Vyvgart growth - Investing.com
argenx SE (ARGX) Stock Price, Trades & News - GuruFocus
Argenx SE stock (NL0010832176): FMR LLC boosts stake amid price gains - AD HOC NEWS
Earnings call transcript: Argenx Q1 2026 beats EPS expectations, stock dips - Investing.com
Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular Disease - Sahm
argenx stock gains after FDA expands MG treatment approval By Investing.com - Investing.com South Africa
argenx stock gains after FDA expands MG treatment approval - Investing.com
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG - ChartMill
RBC Capital maintains argenx stock price target at $890 on uptake potential - Investing.com Australia
Earnings call transcript: Argenx beats EPS forecast in Q1 2026 By Investing.com - Investing.com Australia
Earnings call transcript: Argenx beats EPS forecast in Q1 2026 - Investing.com
Argenx beats profit forecasts despite revenue miss - Investing.com
Argenx beats profit forecasts despite revenue miss By Investing.com - Investing.com Canada
argenx posts 63% revenue growth on strong Vyvgart sales By Investing.com - Investing.com South Africa
大文字化:
|
ボリューム (24 時間):